Risk Factors for Multidrug-resistant Tuberculosis
Diabetes mellitus has been a well-known risk factor for TB in the past. The global convergence of the accelerating type 2 DM pandemic, high TB prevalence and drug-resistant TB during the past couple of decades has become a serious challenge to clinicians worldwide. Over the past few years, some studies have shown that the treatment failure rate is higher in TB patients with DM as comorbidity. Moreover, there is significant association between DM an MDR-TB. There is higher chance of TB bacilli persistence to be present in sputum of pulmonary TB patient with DM than TB-only patient after 5 months treatment, and this persistence made it necessary for more longer treatment. Presence of DM in TB patients cause a longer period for sputum conversion, therefore it may become a major cause of poor treatment outcome in TB patients. Previous studies showed that a major mechanism for the emergence of drugs resistance in TB bacilli is random mutation in the bacterial genome and the pressure of selection by anti-TB drugs. Pulmonary TB in diabetic patients usually show higher mycobacterial loads at the initiation of treatment, hence they may have higher chance of bacillary mutation and the emergence of MDR-TB with the presenting of higher bacterial loads, longer treatment is needed to clear the bacteria. Therefore, it is not suprising that a higher chance of MDR-TB patients could be find in those patients. A pharmacokinetic study noted that plasma levels of rifampicin were 53% lower in TB patients with diabetes, which might affect treatment outcomes. Inadequate immune respons of the host may also be important in this negative effect of diabetes. Depressed production of IFN-γ in diabetic patients is related to decreasing immune response to TB infection. Reduction of IL-12 response to mycobacterial stimulation in leukocytes from TB with diabetic patients suggest a compromise of innate immune response.
Petunjuk teknis pengobatan pasien TB resisten obat dengan paduan standar jangka pendek di Fasyankes TB resisten obat. Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pencegahan dan Pengendalian Penyakit, 2017.
Generic programmatic and clinical guide for the introduction of new drugs and shorter regimen for the treatment of Multi/Extensively Drug-Resistant Tuberculosis. KNCV Tuberculosis Foundation, 2016.
Jain A, Dixit P. Multidrug-resistant to extensively drug resistant tuberculosis: What is next? J Biosci. 2008;33: 605-16.
Rifat M, Milton AH, Hall J, et al. Development of multidrug-resistant tuberculosis in Bangladesh: A case-control study on risk factors. PLOS ONE. 2014;9:1-7.
Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug-resistant tuberculosis patients in Ambara National Regional State. African Health Sciences. 2015;15:368-77.
Matteeli A, Roggi A, Carvalho ACC. Extensively drug-resistant tuberculosis: epidemiology and management. Clinical Epidemiology. 2014;6:111-8.
Farazi A, Sofian M, Zarrinfar N, Katebi F, Hoseini SD, Keshavarz R. Drug resistance pattern and associated risk factors of tuberculosis patients in the central province of Iran. Caspian J Intern Med. 2013;4:785-9.
Lomtadze N. Aspindzelashvili R, Janjgava M, et al. Prevalence and risk factors for multidrug-resistant tuberculosis in Republic of Georgia: A population based study. Int J Tuberc Lung Dis. 2009;13:68-73.
Jenn-Tyang C, Homg-Yunn D, Chia-Liang Y, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: A potential role in the emergence of multidrug-resistance. J Formos Med Assoc. 2011;110:372-81.
Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of anti-tuberculosis therapy. Clinical Infectious Diseases. 2012;55:169-77.
- There are currently no refbacks.